4-(2-furyl)pyridine | 55484-04-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-(2-furyl)pyridine
• 英文别名: 4-(furan-2-yl)-pyridine；4-(furan-2-yl)pyridine
• CAS: 55484-04-3
• 化学式: C₉H₇NO
• mdl: MFCD27500707
• 分子量: 145.161
• InChiKey: ZKFCBMREQURXHM-UHFFFAOYSA-N

物化性质

• 熔点：
  69 °C
• 沸点：
  110 °C(Press: 0.6 Torr)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(2-furyl)pyridine 在 正丁基锂 、 tris(dibenzylideneacetone)dipalladium (0) 、 硫代水杨酸 、 1,4-双(二苯基膦)丁烷 作用下， 以 四氢呋喃 、 乙二醇二甲醚 为溶剂， 生成 (S)-4-[1-Methyl-1-(5-pyridin-4-yl-furan-2-yl)-ethyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide
  参考文献：
  名称：

  HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent

  摘要：

  A biaryl pyridylfuran P-3 substituent on the hydroxyethylene isostere scaffold affords HIV protease inhibitors (PI's) with picomolar (IC50) potency against the protease enzymes from PI-resistant HIV-1 strains. Inclusion of a gem-dimethyl substituent afforded compound 3 with 100% oral bioavailability (dogs) and more than double the t(1/2) of indinavir. Inhibition of multiple P450 isoforms is dependent on the regiochemistry of the pyridyl nitrogen in these compounds. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00475-x
• 作为产物：
  描述：

  异烟酰乙酸乙酯 在 氢氧化钾 、 ammonium hydroxide 、 铜 作用下， 以 乙醇 为溶剂， 220.0 ℃ 、1.6 kPa 条件下， 反应 18.5h， 生成 4-(2-furyl)pyridine
  参考文献：
  名称：

  Synthesis and physical properties of the six furylpyridines

  摘要：

  描述了呋喃吡啶的三步合成方法，使用乙基吡啉酰乙酸酯作为2-呋喃化合物的起始物质，氯乙酰吡啶作为3-呋喃异构体的起始物质。此外，这些最后的化合物是通过一种方便的新方法制备的，用于3-取代呋喃的合成。这种合成从溴吡啶开始，通过关键中间体（2,2-二乙氧基乙酰）吡啶和甲基2-(x-吡啶基)-4,4-二乙氧基-2-甲氧基-2-丁烯酸酯进行。已确定了呋喃吡啶的物理性质。通过比较它们的紫外光谱、碱度常数和偶极矩与苯基和噻吩基吡啶的相同性质，讨论了呋喃和吡啶环之间的结构和相互作用。

  DOI：

  10.1139/v83-060

文献信息

• Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides and uses thereof
  申请人：Merck & Co., Inc.

  公开号：US06642237B1

  公开（公告）日：2003-11-04

  &ggr;-Hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamide compounds are inhibitors of HIV protease and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described. These compounds are effective against HIV viral mutants which are resistant to HIV protease inhibitors currently used for treating AIDS and HIV infection.

  -Hydroxy-2-(氟烷基氨基甲酰)-1-哌嗪戊二酰胺化合物是HIV蛋白酶的抑制剂，也是HIV复制的抑制剂。这些化合物在预防或治疗HV感染以及治疗艾滋病方面非常有用，无论是作为化合物、药学上可接受的盐、药物组成成分，还是与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用。还描述了治疗艾滋病的方法以及预防或治疗HIV感染的方法。这些化合物对目前用于治疗艾滋病和HIV感染的HIV蛋白酶抑制剂产生耐药性的HIV病毒突变体具有有效作用。
• Highly Reactive, Single-Component Nickel Catalyst Precursor for Suzuki-Miyuara Cross-Coupling of Heteroaryl Boronic Acids with Heteroaryl Halides
  作者：Shaozhong Ge、John F. Hartwig

  DOI：10.1002/anie.201207428

  日期：2012.12.14

  One for all: The coupling of a range of nitrogen‐ and sulfur‐containing heteroaryl halides with five‐membered nitrogen‐, oxygen‐, and sulfur‐containing heteroaryl boronic acids were achieved in high yields with only 0.5 mol % of the single‐component nickel precatalyst [(dppf)NiCl(cinnamyl)] (dppf=1,1′‐bis(diphenylphosphanyl)ferrocene). The reaction demonstrates good functional group compatibility,

  一劳永逸：一系列含氮和硫的杂芳基卤化物与五元含氮、氧和硫杂芳基硼酸的偶联以高产率实现，单组分仅为 0.5 mol%镍预催化剂 [(dppf)NiCl(肉桂基)] (dppf=1,1'-双(二苯基膦基)二茂铁)。该反应具有良好的官能团相容性，无需干燥箱即可大规模进行。
• [EN] FACTOR IXA INHIBITORS<br/>[FR] INHIBITEURS DU FACTEUR IXA
  申请人：MERCK SHARP & DOHME

  公开号：WO2014120346A1

  公开（公告）日：2014-08-07

  The present invention provides a compound of Formula (I) (structurally represented) wherein R1 is H or C1-6 alkyl, R2 is H or C1-6 alkyl or CH20H, R3 is H or C1-6 alkyl, and R4 is H or C1-6 alkyl, provided that when R1, R2, and R3 are H, R4 is C1-6 alkyl, and when R1, R2, and R4 are H, then R3 is C1-6 alkyl, and when R1, R3, and R4 are H, R2 is C1-6 alkyl or-CH20H, and when R2, R3, and R4 are H, then R1 is C 1-6 alkyl; A is 1 ) a 9-10 membered bicyclic heterocycle having 1-3 heteroatoms independently selected from N, S and 0, which 9-10 membered bicyclic heterocycle is unsubstituted or substituted with R5 and unsubstituted or substituted with R6 and unsubstituted or substituted with NH2, or 2) a 6-9 membered monocyclic or bicyclic carbocyclic ring system unsubstituted or substituted with R5, unsubstituted or substituted with R6, and unsubstituted or substituted with -CH2NH2; and B is 1) a 5- or 6-membered monocyclic heterocycle having 1 or 2 heteroatoms independently selected from N, S or 0, which is unsubstituted or substituted on a carbon or nitrogen atom with R7, unsubstituted or substituted on a carbon or nitrogen atom with R8, and unsubstituted or substituted on a carbon or nitrogen atom with R9, or 2) an 8- or 9-membered fused bicyclic heterocycle having 1, 2 or 3 nitrogen atoms which is unsubstituted or substituted on a carbon or nitrogen atom with R7, and unsubstituted or substituted on a carbon or nitrogen atom with R8; and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses.

  本发明提供了一种式（I）的化合物（结构表示），其中R1为H或C1-6烷基，R2为H或C1-6烷基或CH20H，R3为H或C1-6烷基，R4为H或C1-6烷基，但当R1、R2和R3为H时，R4为C1-6烷基，当R1、R2和R4为H时，R3为C1-6烷基，当R1、R3和R4为H时，R2为C1-6烷基或-CH20H，当R2、R3和R4为H时，R1为C1-6烷基；A为1）具有1-3个异原子（N、S和O中独立选择）的9-10成员双环杂环，该9-10成员双环杂环未取代或取代为R5、未取代或取代为R6、未取代或取代为NH2；或2）未取代或取代为R5、未取代或取代为R6、未取代或取代为-CH2NH2的6-9成员单环或双环碳环系统；B为1）具有1或2个异原子（N、S或O中独立选择）的5-或6成员单环杂环，未取代或在碳或氮原子上取代为R7、未取代或在碳或氮原子上取代为R8、未取代或在碳或氮原子上取代为R9；或2）具有1、2或3个氮原子的8-或9成员融合双环杂环，在碳或氮原子上未取代或取代为R7，并在碳或氮原子上未取代或取代为R8；以及包括一种或多种这些化合物的制药组合物，以及使用这些化合物用于治疗或预防血栓形成的方法。
• Direct C-H Bond Arylation of (Hetero)arenes with Aryl and Heteroarylboronic Acids
  作者：Sankar Guchhait、Maneesh Kashyap、Shuddham Saraf

  DOI：10.1055/s-0029-1219234

  日期：2010.4

  single-electron-transfer oxidative direct C-H bond arylation of (hetero)arenes with aryl and hetero-arylboronic acids. Various electron-deactivated and electron-rich heteroarenes and benzene underwent successfully the direct arylation in this general process. The use of slight excess of heteroarene or benzene in this method was found to be sufficient. cross-coupling - direct arylation - biaryls - single-­electron transfer

  为（杂）芳烃与芳基和杂芳基硼酸的单电子转移氧化直接CH键芳基化开发了一种由Mn（OAc）3介导的新型微波促进协议。在这个一般过程中，各种电子灭活的和富电子的杂芳烃和苯成功地进行了直接芳基化。发现在该方法中使用稍微过量的杂芳烃或苯就足够了。 交叉耦合-直接芳基化-联芳基-单电子转移-微波
• [EN] SRPK1 INHIBITORS<br/>[FR] INHIBITEURS DE SRPK1
  申请人：EXONATE LTD

  公开号：WO2019063996A1

  公开（公告）日：2019-04-04

  Anti-angiogenic treatments, for example treatment of ocular neovascularization or cancer, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of treating or preventing fibrosis and compounds for use in such methods are described.

  本文描述了抗血管生成治疗，例如治疗眼部新生血管病变或癌症，治疗高渗透性疾病，治疗神经病理和神经退行性疾病，疼痛治疗，治疗或预防纤维化的方法以及用于这些方法的化合物。